Teva Pharmaceutical Industries Ltd. Projected to Report US$1.29 EPS for First Quarter of 2015
Published By : 06 May 2015 | Published By : QYRESEARCH
Analysts at Wall Street estimate Teva Pharmaceuticals to report EPS of US$1.29 for the present fiscal quarter. This figure is based on the average estimation of the sell-side research agencies, which cover the stock. Teva Pharmaceuticals recently has reported earnings per share of US$1.36 on April 30, 2015 for the quarter that ended on March 31, 2015. This figure was 0.1 below from what analysts had anticipated a difference of almost 7.94%.
All together, the brokerage analysts provided a consensus price target of US$66 on the Teva stock. This is the average one year estimation based on the fourteen polled research firms that are covering the equity. The recent most price target update, which went into the average, was added on May 01, 2015.
The average broker recommendation is an arithmetical average of the individual ratings contributed by sell-side analysts to produce a Consensus Analyst Rating for each stock. Ratings are scaled on a one to five scale where number five represents a Strong Sell and one represents a Strong Buy. Teva Pharmaceutical Industries Limited currently has a rating of 1.85 based on fourteen research broker recommendations. In this group, the analyst that expects the massive upside to the present stock price foresees it reaching around US$77 in 2015. The most traditional analyst has set the price target at US$48 for the year 2015.
Furthermore, ahead at the growth estimation for the long term for the enterprises, analysts are expecting earnings per share of US$5.3 for the year 2015. The most bullish analyst presents the probability of earnings per share to reach US$5.56, while the most bearish analyst is expecting EPS to reach US$5.08 for 2015.